en · de · es · fr · pt
melanotan-2-notes.peptides6579.com › Blog › Peptide Identity And Structural Background — Explained

Peptide Identity And Structural Background — Explained

By Editorial Desk · published 2026-02-26 · last reviewed 2026-04-08 · Blog

afamelanotide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

This page was last updated on 2026-04-08 and is reviewed periodically as new material appears.

Peptide Identity and Structural Background

The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.

Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.

Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.

Melanotan-2 Identity and Receptor Pharmacology

Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.

Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.

Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.

Melanotan-2 at a glance

PropertyValueNotes
Molecular formulaC50H69N15O9Synthetic cyclic heptapeptide
Molecular massApproximately 1024 g/molDepends on counter-ion content
AppearanceWhite to off-white powderCommonly supplied as a lyophilised solid
SolubilityFreely soluble in waterAlso dissolves in common aqueous buffers
Typical storage-20 degrees Celsius, desiccatedProtect from light and repeated freeze-thaw

Background and Receptor Mechanism

Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.

Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.

Related pages on this site

Chemistry and Receptor Pharmacology

Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.

Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.

Reference notes

charge number A quantized value of electric charge calculated as the electric charge in coulombs divided by the elementary-charge constant, or z = q/e. Charge numbers for ions are denoted in superscript (e.g. Na+ indicates a sodium ion with a charge number of positive one). Atomic numbers are charge numbers of atomic nuclei.

Tina Ruth Coldham. Participation, Involvement and Engagement Advisor, NIHR. For services to Inclusive Patient and Public Involvement in Research. ShelleyJane Coleman. For services to the community in Plymouth, Devon. Robert John Collins. Founder, Pass It On Young Sports Voluntary Youth Organisation. For services to Young People and to Sport. Geraldine Constable. For services to the community in Hailsham and Eastbourne, East Sussex. Rev. Canon Diane Veronica Cookson. For services to St. Saviour's Parish Church and to the community in Stockport, Greater Manchester. Reginald John Cording. For services to the community in Barley, Hertfordshire. Jon-Paul Kitson Cornforth. For services to the community in Rotherham, South Yorkshire, particularly during Covid-19. Margaret Cortis. For voluntary and charitable services to the community in Truro, Cornwall. Robert David Cotterill. For services to Business and to the community in Derbyshire. Chico Cheikh Sadibou Coulibaly. Regional Manager Waterloo, South Western Railway. For services to the State Funeral of Her Majesty Queen Elizabeth II. Noel Desmond Cronin. Founder, Talking Pictures TV. For services to Television Broadcasting. Jill Elaine Crook. Director, Nursing, Professional and System Development, NHS England (South West). For services to Transforming Care, Learning Disability and Autism. David Cupples. For services to the community in County Tyrone. John Andrew Daley. For services to Young People and to the community in Sheffield, South Yorkshire. Anita Davenport-Brooks. Group Human Resources Manager, Lander Automotive.

Chemical pathology, also called clinical chemistry Hematopathology Blood banking - Transfusion medicine Clinical microbiology Cytogenetics Molecular genetics pathology. In some countries other sub specialities fall under certified Clinical Biologists responsibility:

=== Availability === Etifoxine has been marketed in 53 countries as of 2022. Some of the countries in which etifoxine has been marketed include Argentina, Bulgaria, Chile, France, Luxembourg, Malta, Romania, South Africa, Thailand and Ukraine. Etifoxine is not approved for use by the United States Food and Drug Administration (FDA) or the European Medicines Agency (EMA) of the European Union, and hence is not marketed in these regions. However, etifoxine is marketed in five European Union member states (France, Bulgaria, Luxembourg, Malta, Romania) and Ukraine

== Mechanism == Carfilzomib covalently irreversibly binds to and inhibits the chymotrypsin-like activity of the 20S proteasome, an enzyme that degrades unwanted cellular proteins. Carfilzomib displays minimal interactions with non-proteasomal targets, thereby improving safety profiles over bortezomib. Inhibition of proteasome-mediated proteolysis results in a build-up of polyubiquitinated proteins, which may cause cell cycle arrest, apoptosis, and inhibition of tumor growth.

Sources: en.wikipedia.org

Reference notes

On November 12, 2024, President-elect Donald Trump named Hegseth as his nominee for secretary of defense, after Arkansas senator Tom Cotton announced he would not serve as secretary. Hegseth subsequently ended his contract with Fox News. The selection of Hegseth was seen as a sign that Trump sought to appoint a loyalist to lead the Department of Defense, and his relative lack of experience surprised officials in the department. According to Vanity Fair, Trump's transition team became aware the following day of a sexual assault allegation involving Hegseth that occurred in Monterey, California, seven years prior; The Washington Post reported that senior officials on the team were surprised by the allegation and reconsidered his nomination. Despite the allegation, Trump defended Hegseth and several Republican senators indicated that they would support him. His nomination was threatened by an article from Jane Mayer in The New Yorker detailing alleged financial mismanagement and alcohol issues while leading his veterans' groups, while an NBC News article reported that his drinking habits concerned his colleagues at Fox News; The New York Times reported in December that Trump had begun to consider Florida governor Ron DeSantis as an alternative. In an effort to retain his nomination amid controversies, Hegseth began a campaign that month. Advisors to Trump privately sought to persuade him to support Hegseth in fear that it would embolden recalcitrant Republican senators, while he could not garner support for DeSantis, according to The New York Times.

==== College of Interdisciplinary and Continuing Studies ==== The College of Interdisciplinary and Continuing Studies provides degree programs to learners with previously earned college credits but no degree, affording the opportunity of degree completion. The interdisciplinary nature of the programs allows students to draw from expertise and resources across campus to design a program of study aligned with local, national and global workforce opportunities.

Thrombocytopenia a significant drop in platelet count that leaves one open to life-threatening bleeds. Eosinophilia an elevated level of the eosinophils of the body. Eosinophils are the type of immune cell that's job is to fight off parasitic invaders. Jaundice yellowing of the skin, eyes and mucous membranes due to an impaired ability of the body to clear the by product of haem breakdown, bilirubin, most often the result of liver damage as it is the liver's responsibility to clear bilirubin. It tends to produce less anticholinergic effects, sedation and weight gain than some of the earlier TCAs (e.g. amitriptyline, clomipramine, doxepin, imipramine, trimipramine). It may also be less cardiotoxic than its predecessors.

== Chemistry == 1,2-Diarylethylamines contain the substructure ArCH2CH(Ar')NRR', where Ar, Ar' = aryl and R, R' = H or organyl. A chiral center exists at the ethylamine carbon atom bearing the two aryl groups. The enantiomers often have a large difference in pharmacological activity. For example, (+)-(S)-diphenidine has 40 times higher affinity than (−)-(R)-form for the NMDA receptor. According to a review by Jason Wallach and Simon Brandt (2018), most psychoactive 1,2-diarylethylamines reported in the scientific literature contain non-heteroaromatic aryl groups (i.e., both rings are carbocyclic). Some exceptions include lanicemine and an analogue N-ethyl-lanicemine, which feature a heteroaromatic pyridyl ring. Additional heteroaromatic analogues have been disclosed in the patent literature.

Sources: en.wikipedia.org

Frequently asked questions

What is Melanotan-2 chemically?

It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.

How does it differ from the natural hormone?

It is shorter than the native hormone and carries a cyclic constraint that improves stability. These changes raise receptor potency and slow breakdown relative to the naturally occurring peptide.

When was Melanotan-2 first described?

Published accounts date its development to the 1980s, when researchers were generating analogues of melanocyte-stimulating hormone. That work aimed to produce more stable compounds for studying pigmentation biology.

What is melanotan-2 chemically?

It is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, containing seven amino acids with a lactam ring and a D-configured phenylalanine residue. It is supplied as a lyophilised powder for laboratory research.

Network